Eloralintide Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Eloralintide Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Phase 3
Highest phase
20
Registered trials
5
Result records
10
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Eloralintide can convert its Recombinant polypeptide profile and AMYR biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Eloralintide (query alias: eloralintide) |
|---|---|
| Modality / target | Recombinant polypeptide; AMYR; AMYR agonists |
| Highest global status | Phase 3 |
| Originator | Eli Lilly & Co. |
| Active developers | Eli Lilly (Beijing) Medical Technology Innovation Co., Ltd., Incog Biopharma, Eli Lilly & Co. |
The MCP disease footprint includes Sleep Apnea, Obstructive, Osteoarthritis, Knee, Diabetes Mellitus, Type 2. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| CTR20262449 | Phase 3 | 进行中 （尚未招募） | 90 | Not disclosed |
| CTR20261932 | Phase 3 | 进行中 （尚未招募） | 70 | Not disclosed |
| NCT07665879 | Phase 1 | Not yet recruiting | 115 | Change From Baseline In Hyperinsulinemic Euglycemic Clamp (HEC) Predicted Clamp-Derived Insulin Sensitivity (M-value) |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
A Phase 2, Parallel-Group, Double-Blind Study to Investigate Weight Management With LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight
Phase 2; n=263; evaluation: not stated. Reported fields: Percent Change From Baseline in Body Weight at Week 48(Least Squares Mean) = -0.4 percent change (Standard Error, 0.91); -; -
Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept
Phase 1; n=48; evaluation: Positive. Reported fields: AE = Nine participants in the eloralintide cohorts reported 16 adverse events, with most being mild (n=15/16). Two participants reported 4 gastrointestinal events, including one moderate vomiting event. Event ; AE = 16.0 Event
Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial
Phase 2; n=263; evaluation: Positive. Reported fields: Bodyweight(48 weeks) = -20.0 % ( -22.7 to -17.0); Bodyweight(48 weeks) = -20.0 % ( -22.7 to -17.5); Bodyweight(48 weeks) = -16.0 % ( -18.6 to -14.1)
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Eloralintide addresses Sleep Apnea, Obstructive, Osteoarthritis, Knee, Diabetes Mellitus, Type 2. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Recombinant polypeptide—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 10 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: AMYR records as comparable precedents only.
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2025-09-22 | Pfizer Closes Metsera Deal, Officially Ending Bidding War Drama | Phase 1/2 | US$7,600.0M upfront; US$2,400.0M milestones; US$10,000.0M stated total |
| 2025-03-12 | Roche enters into an exclusive collaboration & licensing agreement with Zealand Pharma to co-develop and co-commercialise petrelintide as a potential foundational therapy for people with overweight and obesity | Phase 2 | US$1,650.0M upfront; US$3,600.0M milestones; US$5,300.0M stated total |
| 2025-03-03 | AbbVie and Gubra Announce License Agreement to Develop an Amylin Analog for the Treatment of Obesity | Phase 1 | US$350.0M upfront; US$1,875.0M stated total |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Class crowding and differentiation versus other PD-(L)1/VEGF agents
- Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
- Biomarker strategy, indication selection, and head-to-head endpoint execution
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
